Showing 1641-1650 of 4063 results for "".
- EyeQue to Launch VisionCheck 2 Do-It-Yourself Smartphone Vision Testhttps://modernod.com/news/eyeque-to-launch-visioncheck-2-do-it-yourself-smartphone-vision-test/2478648/EyeQue announced the upcoming launch of EyeQue VisionCheck 2, a refraction device available for consumers to test their own vision and order new glasses from home. VisionCheck 2 is a lightweight optical smartphone attachment and mobile app. The test results are expr
- Pfizer, BioNTech Begin Phase 2/3 Coronavirus Vaccine Studyhttps://modernod.com/news/pfizer-biontech-pick-bnt162b2-to-advance-into-phase-2-3-coronavirus-vaccine-study/2478084/Pfizer and partner BioNTech said they have decided to advance the nucleoside-modified mRNA vaccine candidate BNT162b2 into phase 2/3 testing. The vaccine, to be trialed at the 30-mcg dose as part of a two-dose regimen, encodes for an optimized SARS-CoV-2 full-length spike glycoprotein, which the
- I-MED Pharma Becomes Authorized Canadian Distributor for OrCam MyEye 2https://modernod.com/news/i-med-pharma-becomes-authorized-canadian-distributor-for-orcam-myeye-2/2476463/I-MED Pharma, a Canadian company specializing in dry eye diagnosis and management, announced the signing of an authorized Canadian distribution agreement with OrCam for its MyEye 2 assistive technology device for the blind and visually impaired. The OrCam MyEye 2 is a tiny, portable, artif
- DigitalOptometrics Surpasses 2 Million Remote Eye Examshttps://modernod.com/news/digitaloptometrics-surpasses-2-million-remote-eye-exams/2482242/DigitalOptometrics announced it has surpassed 2 million remote comprehensive eye exams. DigitalOptometrics' remote eye exam platform is designed to allow optometrists to conduct comprehensive eye exams remotely, integrating video conferencing with remote operation of opht
- First Patient Treated in Multicenter Trial Examining Allotex TransForm Allogenic Refractive Lenticules for Treatment of Presbyopiahttps://modernod.com/news/first-patient-treated-in-multicenter-trial-examining-allotex-transform-allogenic-refractive-lenticules-for-treatment-of-presbyopia/2479889/Start-up ophthalmic device company Allotex announced the commencement of a European multicenter trial for its investigational TransForm allogenic refractive lenticules for the treatment of presbyopia. The treatment was performed on Thursday by Arthur Cummings, MB ChB, FCS(SA), MMed(Ophth)
- White House and Senate Strike a Deal on $2 Trillion Coronavirus Stimulus Billhttps://modernod.com/news/white-house-and-senate-strike-a-deal-on-historic-2-trillion-coronavirus-stimulus-bill/2477454/The White House and Senate leaders reached a deal early Wednesday on a massive $2 trillion relief bill—said to be the largest rescue package in American history—to combat the economic impact of the coronavirus outbreak, according to a CNBC
- Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitishttps://modernod.com/news/nicox-initiates-phase-2-trial-of-ncx-4251-in-blepharitis/2476393/Nicox SA announced the initiation of a phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatm
- Eyenovia Announces Positive Results From VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia/2481181/Eyenovia announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia. The VISION-2 study evaluated the safety and efficacy of Eyenovia’s 2% pilocarpine micro-array print (MAP) formulation versus placebo, all administered
- FDA Officially Shifts to One-Trial Standard for New Drug Approvalshttps://modernod.com/news/fda-officially-shifts-to-one-trial-standard-for-new-drug-approvals/2485753/The FDA has announced a major change to its regulatory framework, formally establishing that a single well-designed pivotal clinical trial will be the new default basis for most drug and therapeutic approvals—replacing the long-standing expectation that two indepen
- Galimedix Therapeutics Initiates Phase 2 Study with GAL-101 Eye Drops in Dry AMDhttps://modernod.com/news/galimedix-therapeutics-initiates-phase-2-study-with-gal-101-eye-drops-in-dry-amd/2482590/Galimedix Therapeutics announced the initiation of a phase 2 study (eDREAM;